Hospital Injectable Products · LP-181
Cyanocobalamin (Vitamin B12) Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-181Hospital Injectable Products
- Generic identity
- Cyanocobalamin (Vitamin B12)Injection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-181
- Generic ingredient
- Cyanocobalamin (Vitamin B12)
- Dosage form
- Injection
- Proposed strength
- 1000 mcg/mL
- Proposed pack
- Ampoule 1 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
About Cyanocobalamin (Vitamin B12)
Cyanocobalamin is a form of vitamin B12, a nutrient needed for normal blood-cell formation and neurological function. It is used in defined vitamin B12-deficiency contexts. Oral and injectable presentations differ in their clinical role and administration. The best route depends on the cause and severity of deficiency and other patient factors; the ingredient name alone does not establish that an injection or tablet is appropriate.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Clinical review distinguishes dietary insufficiency from malabsorption, pernicious anaemia or other causes. Neurological symptoms and blood findings may require prompt assessment and follow-up. Vitamin B12 supplementation is not a general treatment for fatigue without evaluation. References can describe several B12 forms, including hydroxocobalamin, but those formulations must not be represented as chemically identical to cyanocobalamin. The catalogue does not provide a replacement schedule or confirm an authorized indication.
Important safety considerations
Allergy, including reactions relevant to cobalt sensitivity, should be considered. Injectable products can cause local reactions and, rarely, serious hypersensitivity. Rapid correction of severe anaemia can require clinical and electrolyte monitoring. Certain inherited optic-nerve conditions and significant comorbid disease require label-specific assessment. Persistent neurological symptoms must not be dismissed because a supplement has been started. Coexisting folate or iron problems may also need investigation.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
Tablet and injection entries must remain distinct. Confirm the exact vitamin B12 form, strength per unit and, for injection, preservative composition and route. A label for hydroxocobalamin or a nasal product is not proof of cyanocobalamin formulation equivalence.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm deficiency, its likely cause, neurological features, allergy history and the follow-up plan. Select a verified route and formulation using the current local label.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Cyanocobalamin (Vitamin B12)
- Dosage form / presentation
- Injection
- Catalogue strength
- 1000 mcg/mL
- Catalogue pack
- Ampoule 1 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- The catalogue establishes cyanocobalamin injection at 1000 mcg/mL in a 1 mL ampoule but does not establish authorised route, preservative system, dilution/compatibility or administration protocol.
- The tablet and injection records remain separate; shared ingredient identity does not establish substitution or dose conversion.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NIH ODS: Vitamin B12 — Health Professional Fact Sheetgovernment scientific fact sheet
- MedlinePlus: Cyanocobalamin Injectiongovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming exact active chemical form, concentration or vial content, container/fill, authorised route(s), excipients/preservatives and preparation/compatibility controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-181, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-181.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.